genenta.com (GNTA) Cash Funds per Single Share

Genenta Science S.p.A. (GNTA) relies on grants and capital due to a lack of sales and negative FCF. An analysis of cash per share links this balance to the prospect of treating glioblastoma through personalized medicine. The value of 0.68 determines the latest valuation metric, highlighting the Italian biotech's dependence on clinical trial results in the complete absence of market pricing power.
Comprehensive metric breakdowns and analytics for genenta.com (GNTA)

This metric is calculated by dividing the total volume of liquid cash by the total number of shares outstanding. The metric determines the actual cash reserve available per share of capital to cover operating expenses or investments. For Genenta Science S.p.A. (GNTA), this reserve is critical when financing costly developments in brain tumor gene therapy. Liquidity dynamics allow for an assessment of the innovator's financial stability during periods of clinical trials. By analyzing changes in cash per share, an investor can see the balance between risk mitigation and resource efficiency.